Provided by Tiger Fintech (Singapore) Pte. Ltd.

Genmab A/S

21.71
-0.3200-1.45%
Volume:115.72K
Turnover:2.51M
Market Cap:13.37B
PE:11.82
High:21.80
Open:21.73
Low:21.65
Close:22.03
Loading ...

Genmab A/S Stock Falls Friday, Outperforms Market

Dow Jones
·
05 Apr

Genmab A/S Stock Falls Wednesday, Underperforms Market

Dow Jones
·
03 Apr

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

GlobeNewswire
·
02 Apr

Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts?

Insider Monkey
·
01 Apr

Genmab A/S Stock Falls Monday, Outperforms Market

Dow Jones
·
01 Apr

Genmab Says European Commission Grants Marketing Authorization for Tivdak as Cervical Cancer Treatment

MT Newswires Live
·
01 Apr

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

Benzinga
·
28 Mar

Genmab A/S Stock Rises Thursday, Outperforms Market

Dow Jones
·
28 Mar

Genmab Says Japan Approves Tivdak for Cervical Cancer

MT Newswires Live
·
27 Mar

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Business Wire
·
27 Mar

Genmab A/S Stock Falls Monday, Underperforms Market

Dow Jones
·
25 Mar

Sector Update: Health Care Stocks Edge Higher Premarket Monday

MT Newswires Live
·
24 Mar

Genmab Denies Trade Secret Misappropriation Claims by AbbVie

MT Newswires Live
·
24 Mar

Genmab A/S Stock Falls Friday, Outperforms Market

Dow Jones
·
22 Mar

Genmab A/S Stock Falls Wednesday, Underperforms Market

Dow Jones
·
20 Mar

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

GlobeNewswire
·
18 Mar

Genmab A/S Stock Falls Thursday, Underperforms Market

Dow Jones
·
14 Mar

Morgan Stanley Remains a Hold on Genmab (GMAB)

TIPRANKS
·
13 Mar

Genmab Is Maintained at Buy by Truist Securities

Dow Jones
·
12 Mar

Genmab Raised to Outperform From Market Perform by William Blair

Dow Jones
·
11 Mar